Page last updated: 2024-10-29

ketoconazole and Neoplasm Metastasis

ketoconazole has been researched along with Neoplasm Metastasis in 24 studies

1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

ExcerptRelevanceReference
"These results indicate that ketoconazole significantly reduced hepatic metastases from the human pancreatic carcinoma RWP-2 in the nude mouse model, and inhibited thromboxane B2 formation, potentiating a concomitant redirection of platelet endoperoxide metabolism into PGD2, PGE2, and 6-keto-F1a."3.71The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. ( Krambovitis, E; Tsatsakis, AM; Tzanakakis, GN; Vezeridis, MP, 2002)
"Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy."2.73Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. ( Brown, MA; Do, KA; Logothetis, CJ; Millikan, RE; Moomey, B; Pagliaro, LC; Wen, S, 2008)
"Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing."2.73A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008)
"Ketoconazole action dosed as 400-600 g per day was studied in 12 patients with prostatic metastasizing carcinoma."2.67[Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma]. ( Morávek, P; Zita, K, 1991)
"Almost all patients with prostatic cancer will eventually escape the control of the first-line endocrine therapy and relapse."2.38Management of relapsing disease in prostate cancer. ( Denis, L; Mahler, C, 1992)
"Prednisone use was associated with a reduced risk of progression on docetaxel in the propensity score-weighted multivariable Cox model (P=0."1.43The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. ( Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA, 2016)
"Invasion and metastasis are responsible for 90% of cancer-related mortality."1.424-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model. ( Bracke, ME; De Ryck, T; Katritzky, AR; Patronov, A; Roman, BI; Slavov, SH; Stevens, CV; Vanhoecke, BW, 2015)
"Ketoconazole (KT) is a less potent CYP17 inhibitor previously widely used in mCRPC."1.40Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. ( Alimohamed, N; Atenafu, EG; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE, 2014)
"Ketoconazole can suppress androgen production and has a beneficial role in the hormonal therapy of patients with prostate cancer who have not undergone orchiectomy."1.27High-dose ketoconazole therapy in patients with metastatic prostate cancer. ( Al-Sarraf, M; Decker, DA; Kresge, C; Subramanian, MG; Tapazoglou, E, 1986)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19907 (29.17)18.7374
1990's5 (20.83)18.2507
2000's4 (16.67)29.6817
2010's8 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Roman, BI1
De Ryck, T1
Patronov, A1
Slavov, SH1
Vanhoecke, BW1
Katritzky, AR1
Bracke, ME1
Stevens, CV1
Almassi, N1
Reichard, C1
Li, J1
Russell, C1
Perry, J1
Ryan, CJ2
Friedlander, T1
Sharifi, N1
Leibowitz-Amit, R1
Seah, JA1
Atenafu, EG1
Templeton, AJ1
Vera-Badillo, FE1
Alimohamed, N1
Knox, JJ1
Tannock, IF1
Sridhar, SS1
Joshua, AM1
Kim, W1
Zhang, L1
Wilton, JH1
Fetterly, G1
Mohler, JL1
Weinberg, V1
Morse, A1
Szmulewitz, RZ1
Friedlander, TW1
Fong, L1
Lin, AM1
Harzstark, AL1
Molina, A1
Small, EJ2
Teply, BA1
Luber, B1
Denmeade, SR1
Antonarakis, ES1
Millikan, RE1
Wen, S1
Pagliaro, LC1
Brown, MA1
Moomey, B1
Do, KA1
Logothetis, CJ1
Figg, WD1
Woo, S1
Zhu, W1
Chen, X1
Ajiboye, AS1
Steinberg, SM1
Price, DK1
Wright, JJ1
Parnes, HL1
Arlen, PM1
Gulley, JL1
Dahut, WL1
Pond, GR1
Armstrong, AJ1
Galsky, MD1
Wood, BA1
Leopold, L1
Sonpavde, G1
Lin, GW1
Yao, XD1
Ye, DW1
Zhu, Y1
Zhang, SL1
Dai, B1
Zhang, HL1
Shen, YJ1
Ma, CG1
Tzanakakis, GN1
Krambovitis, E1
Tsatsakis, AM1
Vezeridis, MP1
Yong, WP1
Wang, LZ1
Tham, LS1
Wong, CI1
Lee, SC1
Soo, R1
Sukri, N1
Lee, HS1
Goh, BC1
Spors, S1
Möller, A1
Baron, AD1
Fippin, L1
Apodaca, D1
Bare, RL1
Torti, FM1
Rickman, T1
Garmany, R1
Doherty, T1
Benson, D1
Okusa, MD1
Mahler, C1
Denis, L1
Morávek, P1
Zita, K1
Lowe, FC1
Bamberger, MH1
Tapazoglou, E1
Subramanian, MG1
Al-Sarraf, M1
Kresge, C1
Decker, DA1
Oelschläger, H1
Rothley, D1
Dunzendorfer, U1
Eichenberger, T1
Trachtenberg, J1
Debruyne, FM1
Witjes, FA1
Castillo Cádiz, O1
Martínez Sanz, P1
Dubost, JJ1
Sauvezie, B1
Ristori, JM1
Thevenet, JP1
Rampon, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate[NCT00002855]Phase 3306 participants (Actual)Interventional1996-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for ketoconazole and Neoplasm Metastasis

ArticleYear
Endocrine therapy of prostate cancer.
    Cancer treatment and research, 1998, Volume: 94

    Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti

1998
Management of relapsing disease in prostate cancer.
    Cancer, 1992, Jul-01, Volume: 70, Issue:1 Suppl

    Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens

1992
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
    Revue du rhumatisme et des maladies osteo-articulaires, 1985, Volume: 52, Issue:10

    Topics: Aminoglutethimide; Androgen Antagonists; Animals; Antineoplastic Agents; Combined Modality Therapy;

1985

Trials

7 trials available for ketoconazole and Neoplasm Metastasis

ArticleYear
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Dec-15, Volume: 20, Issue:24

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgens; Androstenes; Humans; Ketoconazole; Male; Mi

2014
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-20, Volume: 26, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Ag

2008
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
    The Journal of urology, 2010, Volume: 183, Issue:6

    Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interacti

2010
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Urologic oncology, 2013, Volume: 31, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Hu

2013
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2

    Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R

2008
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
    The Journal of urology, 1997, Volume: 157, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy

1997
[Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma].
    Sbornik vedeckych praci Lekarske fakulty Karlovy univerzity v Hradci Kralove. Supplementum, 1991, Volume: 34, Issue:5

    Topics: Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms

1991

Other Studies

14 other studies available for ketoconazole and Neoplasm Metastasis

ArticleYear
4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.
    European journal of medicinal chemistry, 2015, Aug-28, Volume: 101

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Cell Movement; Ce

2015
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
    JAMA oncology, 2018, Apr-01, Volume: 4, Issue:4

    Topics: Aged; Alleles; Androgen Antagonists; Biomarkers, Tumor; Gain of Function Mutation; Gene Expression R

2018
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:14

    Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols;

2014
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2016, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S

2016
The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
    Asian journal of andrology, 2012, Volume: 14, Issue:5

    Topics: Aged; Humans; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms

2012
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
    International journal of gastrointestinal cancer, 2002, Volume: 32, Issue:1

    Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Animals; Antineoplastic Agents; Dinoprostone; Humans;

2002
[Malignant hemangiopericytoma. Candida meningitis under ketoconazole therapy].
    MMW, Munchener medizinische Wochenschrift, 1983, Nov-11, Volume: 125, Issue:45

    Topics: Adult; Candidiasis; Female; Hemangiopericytoma; Humans; Ketoconazole; Leukopenia; Meningitis; Neopla

1983
Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 37, Issue:4

    Topics: ACTH Syndrome, Ectopic; Adenocarcinoma; Adrenocorticotropic Hormone; Aged; Alkalosis; Comorbidity; C

2001
Indications for use of ketoconazole in management of metastatic prostate cancer.
    Urology, 1990, Volume: 36, Issue:6

    Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Contraindications; Estrogens; Humans; Ketoconazol

1990
High-dose ketoconazole therapy in patients with metastatic prostate cancer.
    American journal of clinical oncology, 1986, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Aged; Androstenedione; Combined Modality Therapy; Dehydroepiandrosterone; Dexamethas

1986
[Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
    Arzneimittel-Forschung, 1988, Volume: 38, Issue:10

    Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Bi

1988
Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer.
    American journal of clinical oncology, 1988, Volume: 11 Suppl 2

    Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Humans; Ketoconazole; Male; Middle

1988
Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.
    Progress in clinical and biological research, 1987, Volume: 243A

    Topics: Estrogens; Humans; Hydrocortisone; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prostatic N

1987
[Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
    Revista medica de Chile, 1985, Volume: 113, Issue:4

    Topics: Acid Phosphatase; Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neop

1985